Condition: Breast Cancer Invasive · Sponsor: Shanghai Jiao Tong University School of Medicine
To explore the efficacy of 68Ga-GZMB PET/CT in assessing the response to neoadjuvant therapy for breast cancer, and to investigate the optimal SUVmax threshold of 68Ga-GZMB PET/CT for predicting pathological complete response (pCR), aiming to provide a new and effective means for accurately and non-invasively evaluating the efficacy of neoadjuvant therapy.
This description comes directly from the study's public registry record.
Xiaosong Chen · +86-21-64370045-602102 · chenxiaosong0156@hotmail.com
Siji Zhu · +86-21-64370045-602102 · zsj_mu@yeah.net
Always discuss trial participation with your own doctor first.
| Shanghai Jiaotong University School of Medicine affiliated Ruijin Hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06725940